Newsroom

Download PDF BOSTON, June 3, 2025 (PR Newswire) – AVEO Oncology, an LG Chem company (“AVEO”), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, presented three posters during the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago, IL, including one exploratory sub-analysis for tivozanib and two trials

Download PDF BOSTON, April 28, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, announced today that three abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) 2025 annual meeting this May 30-June 3, 2025, in

Download PDF – Cumulative data of three Phase 3 studies demonstrate greater exposure of tivozanib is associated with increased clinical benefit ––  Patient Reported Outcomes were numerically better for patients receiving tivozanib in a second line setting versus third line – BOSTON, Feb. 18, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), is

Download PDF BOSTON, Feb. 12, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, announced today two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) 2025 meeting this February 13-15, 2025, in San

Download PDF – TiNivo-2 FOTIVDA® (tivozanib) monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line immune checkpoint inhibitor (ICI) combinations – – TIVO-3 Exploratory Overall Survival (OS) Analysis Provides Additional Data for FOTIVDA Following Immunotherapy – – Safety results support the well-established safety profile of FOTIVDA – BOSTON, September 16, 2024

Download PDF BOSTON, September 3, 2024 (PR Newswire) – AVEO Oncology, an LG Chem company (“AVEO”), announced today their late-breaking abstract detailing their Phase 3 TiNivo-2 trial has been selected as a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain this September 13-17th. The oral presentation

Download PDF – The addition of nivolumab to low dose tivozanib after prior immune checkpoint inhibitor (ICI) is not superior to standard dose tivozanib alone; as a result, the primary endpoint was not met – – Tivozanib monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line ICI combinations – – Safety

Download PDF – LG Chem to embark on developing Next-Generation Immune Checkpoint Inhibitors to Provide Solid Tumor Treatment Solutions – – LG Chem and AVEO Oncology continuing to advance its shared vision of becoming a leading global oncology company – BOSTON, June 13, 2024 (PR Newswire) — LG Chem and AVEO Oncology, an LG Chem